Statistics from Altmetric.com
- ACE, angiotensin converting enzyme
- HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A
- PREFACE, pravastatin-related effects following angioplasty on coronary endothelium
Endothelial dysfunction is an early event in atherogenesis and is associated with the propensity to cause future cardiovascular events. The amelioration of endothelial dysfunction has been a research target for some years now, and success has been reported with, for example, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Research has also identified the homozygous deletion (DD) subset of the angiotensin converting enzyme (ACE) insertion(I)/deletion(D) polymorphism to be associated with deteriorated endothelial function. The results, however, are conflicting. In a substudy of the PREFACE (pravastatin-related effects following angioplasty on coronary endothelium) trial1 we assessed ACE polymorphism, coronary endothelial function, and the influence of the HMG-CoA reductase inhibitor pravastatin.
PREFACE1 was a randomised, double blinded, placebo controlled, multicentre study designed to assess the effect of three months of treatment with pravastatin (40 mg, once daily) on the endothelial function of native and dilated coronary arteries in non-smoking, non-hypercholesterolaemic patients.
Coronary endothelium dependent vasomotion at three months was assessed by serial, two minute, intracoronary infusions of acetylcholine with the final intracoronary concentrations estimated to be 10-8, 10-7, and 10-6 M. Hereafter …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.